| Kabra Drugs has reported a standalone sales turnover of Rs 2.51 crore and a net profit of Rs 0.03 crore for the quarter ended Dec '12. | | For the quarter ended Dec 2011 the standalone sales turnover was Rs 1.56 crore and net loss was Rs 0.20 crore.. | | Kabra Drugs shares closed at 4.41 on February 08, 2013 (BSE) |
|
| | Kabra Drugs | | Standalone Quarterly Results | -------- in Rs. Cr. -------- |
|
| Dec '12 | Sep '12 | Jun '12 | | | | Sales Turnover | 2.51 | 1.99 | 1.54 | | | | Other Income | -- | -- | -- | | | | Total Income | 2.51 | 1.99 | 1.54 | | | | Total Expenses | 2.42 | 1.96 | 1.30 | | | | Operating Profit | 0.09 | 0.03 | 0.24 | | | | Profit On Sale Of Assets | -- | -- | -- | | | | Profit On Sale Of Investments | -- | -- | -- | | | | Gain/Loss On Foreign Exchange | -- | -- | -- | | | | VRS Adjustment | -- | -- | -- | | | | Other Extraordinary Income/Expenses | -- | -- | -- | | | | Total Extraordinary Income/Expenses | -- | -- | -- | | | | Tax On Extraordinary Items | -- | -- | -- | | | | Net Extra Ordinary Income/Expenses | -- | -- | -- | | | | Gross Profit | 0.09 | 0.03 | 0.24 | | | | Interest | -- | -- | -- | | | | PBDT | 0.10 | 0.04 | 0.24 | | | | Depreciation | 0.07 | 0.07 | 0.07 | | | | Depreciation On Revaluation Of Assets | -- | -- | -- | | | | PBT | 0.03 | -0.03 | 0.17 | | | | Tax | -- | -- | -- | | | | Net Profit | 0.03 | -0.03 | 0.17 | | | | Prior Years Income/Expenses | -- | -- | -- | | | | Depreciation for Previous Years Written Back/ Provided | -- | -- | -- | | | | Dividend | -- | -- | -- | | | | Dividend Tax | -- | -- | -- | | | | Dividend (%) | -- | -- | -- | | | | Earnings Per Share | 0.06 | -- | 0.38 | | | | Book Value | -- | -- | -- | | | | Equity | 4.39 | 4.39 | 4.39 | | | | Reserves | -- | -- | -- | | | | Face Value | 10.00 | 10.00 | 10.00 | | | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
